Evidence map›Paper›PMID 34953400›Full record

ArticleESMO open2022

Results of a single-arm pilot study of

P J Ross, H S Wasan, D Croagh, M Nikfarjam, N Nguyen, M Aghmesheh, A M Nagrial, D Bartholomeusz, A Hendlisz, T Ajithkumar and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Diagnostic accuracy of dual-phaseScientific reports · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 3 countries.

P J RossGuy's & St Thomas' Hospital NHS Foundation Trust, London, UK. Electronic address: paul.ross@gstt.nhs.uk.
H S WasanImperial College Healthcare NHS Trust, London, UK.
D CroaghMonash Health, Clayton, Australia.
M NikfarjamAustin Hospital, University of Melbourne, Australia.
N NguyenRoyal Adelaide Hospital, Adelaide, Australia.
M AghmeshehSouthern Medical Day Care Centre, Wollongong, Australia.
A M NagrialThe Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, Australia.
D BartholomeuszRoyal Adelaide Hospital, Adelaide, Australia.
A HendliszInstitut Jules Bordet, Brussels, Belgium.
T AjithkumarAddenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
C IwujiLeicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester, UK.
N E WilsonOncoSil Medical Limited, Sydney, Australia.
D M TurnerOncoSil Medical Limited, Sydney, Australia.
D C JamesOncoSil Medical Limited, Sydney, Australia.
E YoungSouthern Star Research Pty Ltd, Gordon, Australia.
M T HarrisMonash Health, Clayton, Australia.
Monash Health · AURoyal Adelaide Hospital · AUCambridge University Hospitals NHS Foundation Trust · GBImperial College Healthcare NHS Trust · GBInstitut Jules Bordet · BELeicester Royal Infirmary · GBSt Thomas' Hospital · GBThe University of Melbourne · AUWestmead Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUnresectable locally advanced pancreatic cancer (LAPC) is generally managed with chemotherapy or chemoradiotherapy, but prognosis is poor with a median survival of ∼13 months (or up to 19 months in some studies). We assessed a novel brachytherapy device, using phosphorous-32 ( PATIENTS AND

methodsIn this international, multicentre, single-arm, open-label pilot study, adult patients with histologically or cytologically proven unresectable LAPC received

resultsFifty patients were enrolled and received chemotherapy [intention-to-treat (ITT) population]. Forty-two patients received

conclusionsEndoscopic ultrasound-guided

Indexed as

AdenocarcinomaPancreatic NeoplasmsAdultAlbuminsAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineFluorouracilGemcitabineHumansIrinotecanLeucovorinOxaliplatinPaclitaxelPilot Projects130-nm albumin-bound paclitaxelAlbuminsDeoxycytidineFluorouracilfolfirinoxGemcitabineIrinotecanLeucovorinOxaliplatinPaclitaxel(32)P microparticlesbrachytherapylocal disease control ratelocally advanced pancreatic cancersafety profile

Identifiers

PMID34953400
PMCPMC8717429
OpenAlexW4200326987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.